Meds & supplements › Goserelin
Medicine
ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist
Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗
ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate Palliative treatment of advanced carcinoma of the prostate The management of endometriosis Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women 1.1 Stage B2-C Prostatic Carcinoma ZOLADEX is indicated for use in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate.
Treatment with ZOLADEX and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy. Prostatic Carcinoma ZOLADEX is indicated in the palliative treatment of advanced carcinoma of the prostate. Endometriosis ZOLADEX is indicated for the management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy.
Experience with ZOLADEX for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months. Endometrial Thinning ZOLADEX is indicated for use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding. Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women.
The estrogen and progesterone receptor values may help to predict whether ZOLADEX therapy is likely to be beneficial. The automatic safety feature of the syringe aids in the prevention of needlestick injury.
No formal drug-drug interaction studies have been performed. No confirmed interactions have been reported between ZOLADEX and other drugs.
ZOLADEX, at a dose of 3.6 mg, should be administered subcutaneously every 28 days into the anterior abdominal wall below the navel line using an aseptic technique under the supervision of a physician.
While a delay of a few days is permissible, every effort should be made to adhere to the 28-day schedule.
sofidex [Internet]. Daloreum; c2026. Goserelin; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/goserelin
sofidex. (2026, August 2). Goserelin. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/goserelin
Goserelin. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/goserelin
The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.